// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























914 Abstracts

NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL

E. Volkmann - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

PULMONARY INVOLVEMENT IN ANCA ASSOCIATED VASCULITIS (AAV) ACCORDING TO ANTIGENIC SPECIFICITY: A RETROSPECTIVE ARGENTINE COHORT

C. Pena - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASE: TOBACCO AND OTHER RISK FACTORS

C. Aguilera Cros - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

RISK OF PROGRESSION OF IDIOPATHIC PULMONARY FIBROSIS TO CONNECTIVE TISSUE DISEASE

B. Ghang - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

TREATMENT OF A COHORT OF PATIENTS WITH INTERSTITIAL LUNG DISEASE AND RHEUMATOID ARTHRITIS

C. Aguilera Cros - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Chronic Lymphocytic Leukemia in a Lung Transplant Recipient

A. Arjuna - American Transplant Congress (ATC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Idiopathic pulmonary fibrosis

N/A

Clinical Evaluation of Lung Transplantation for End-Stage Idiopathic Pulmonary Fibrosis Patients with Lung Cancer

J. Zhang - American Transplant Congress (ATC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Idiopathic pulmonary fibrosis

N/A

Blocking the TNF Superfamily member LIGHT to control lung and skin fibrosis

Rana Herro - American Association of Immunologists (AAI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

The Prognostic role of MUC5B rs35705950 genotype in patients with Idiopathic Pulmonary Fibrosis (IPF) on antifibrotic treatment

Nicol Bernardinello - International Workshop on Lung Health (IWLH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

IDIOPATHIC PULMONARY FIBROSIS LEADS TO INCREASED INPATIENT MORTALITY IN PATIENTS ADMITTED FOR ATRIAL FIBRILLATION: ANALYSIS OF INPATIENT SAMPLE

Muhamd Usn Alni - Heart Rhythm Society (HRS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

N/A

Efficacy of MAU868, a Novel BKV Neutralizing Monoclonal Antibody (mAb), for the Treatment of Severe BK Virus Nephropathy (BKVN) After Kidney Transplant

S. C. Jordan - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Idiopathic pulmonary fibrosis

IVIG

Immunomodulation in Lung Transplant May Facilitate Transformation of Usual Interstitial Pneumonia Into Pleuroparenchymal Fibroelastosis

Q. Cai - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

ANGIOGENIC T CELLS AS RELEVANT PLAYERS IN THE LUNG VASCULOPATHY OF RHEUMATOID ARTHRITIS, SYSTEMIC SCLEROSIS AND OTHER AUTOIMMUNE DISEASES

V. Pulito-Cueto - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

CLINICAL COURSE IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES (IPAF): REAL-LIFE DATA FROM A MULTICENTER ILD REGISTRY

C. Vadillo - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

COMPARATIVE FEATURES AND LONGITUDINAL BEHAVIOUR OF RHEUMATOID ARTHRITIS-ASSOCIATED UIP VERSUS IDIOPATHIC PULMONARY FIBROSIS: A SINGLE CENTRE COHORT STUDY

C. Mazeda - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Mycophenolate mofetil

CYTOKINES IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS

B. Zheng - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

Dramatic reduction of mortality rate by tofacitinib in anti-MDA-5 antibody-positive patients with rapidly progressive interstitial lung disease

C. W. Tseng - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Mycophenolic acid

IDENTIFICATION OF RED FLAGS FOR INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS

P. Conigliaro - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

DECREASE OF ANGIOGENIC T CELLS IN CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE

V. Pulito-Cueto - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

USUAL INTERSTITIAL PNEUMONIA DURING RHEUMATOID ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS

C. Daldoul - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

Copyright © 2026. QuantiNova All rights reserved